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Antidiuretic hormone liberated the vertebrates from
their aqueous environment, and permitted them to
establish themselves on dry land. The combination of
sensitive volume and osmoreceptors, a pituitary
secretory apparatus which can vary its output from
virtually zero to high levels in a short space of time,
and receptor cells functioning in the countercurrent
system of the renal medulla, has resulted in a water
conservation system of great efficiency. The hormone
rapidly alters the luminal membrane of receptor cells
in the collecting tubule and collecting duct, increasing
the permeability of these structures to water.1 The
permeability of the collecting duct to urea and sodium
is also increased.
This review will be centered on the sequence of
events that follows the attachment of vasopressin to
its receptors in the distal nephron. This has become an
area of intense activity since the discovery by Suther-
land and his colleagues of the central role of cyclic
AMP in the action of hormones [2]. The review will
cover in brief much of the ground covered by the
extensive review of Handler and Orloff [3], emphasiz-
ing recent additions to the literature. It is regrettable
that the important advances in our understanding of
the synthesis and release of antidiuretic hormone
cannot be included; the reader is referred to recent
symposia and reviews in this area [4—6], as well as in
the comparative physiology of water regulation [7]
and the countercurrent system [8].
1 The distal convoluted tubule is usually also included in the
segments of the nephron affected by vasopressin. Woodhall and
Tisher [1] have questioned this in a recent study of the distal
nephron of the rat, in which swelling of the epithelial cells was
used as an index of vasopressin action. Swelling was not seen in
the distal convoluted tubule, but was apparent along the
collecting tubule and collecting duct.
© 1974, by the International Society of Nephrology.
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Vasopressin levels in plasma
Release of vasopressin. Release of vasopressin from
the pituitary may be triggered by a number of stimuli,
the most important of which are plasma hyperosmo-
lality and volume depletion. A role for the renin-
angiotensin system in regulation of vasopressin secre-
tion has been suggested [9, 10]. Dunn et al [11] have
examined the relative potency of hyperosmolality and
volume depletion in stimulating vasopressin release in
the rat; they found that small changes in blood
osmolality were much more effective than small
changes in volume. When large reductions in volume
were produced, however, arginine vasopressin (AVP)
levels exceeded those produced by hyperosmolality;
volume reduction also appeared to render the osmo-
regulatory system more sensitive to changes in plasma
osmolality.
The extent to which circulating vasopressin is bound
to plasma proteins is uncertain; Lauson [12], in a
review of the studies of binding in human plasma, has
concluded that the data are not wholly consistent, but
seem to indicate that a minor fraction (perhaps less
than one-third) may be bound.
The level of circulating vasopressin in various
physiologic states has been a problem of great interest
and will be considered in the next section.
Radioimmunoassay of A VP. Early estimates of the
circulating level of AVP in man were based primarily
on bioassay techniques [13—16]. Development of an
accurate radioimmunoassay for AVP has been
difficult; however, with refinement of techniques and
acquisition of sensitive and specific antisera [17—20],
several groups have reported values for plasma AVP
under a variety of experimental conditions. The
results of two recent studies with an antiserum de-
veloped by Glick and co-workers [19] are shown in
Table 1 and Fig. 1. While these values must still be
interpreted with caution, some tentative conclusions
may be drawn. The levels of AVP in human serum,
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Table 1. AVP levels as determined by radioimmunoassay
Authors
AVP levels (pg/mi)
BasaI Dehydration
PituitaryDI
Water
diuresis
Husain et al [19]
Robertson eta! [20]
undetect.
0.8±0.3d
0.45
1.4±0.8
3.5
(1.3_7.0)c
2.7± 1.4
3.9
(2.5—8.5)
5.4± 3.4
a DL = diabetes insipidusbad lib water intake
range
1 I SD
translated to niolar concentrations, are in the range of
10- 12 to 10-il M, and are somewhat lower than the
earlier bioassay values. This discrepancy may be due
to technical problems or variation in the physiologic
state of the subjects; however, several authors have
raised the question of an antidiuretic substance in
addition to AVP in human plasma [15, 19, 21]. AVP
release in man has a threshold of approximately 280
mOsm/kg. In normal subjects and subjects with
nephrogenic diabetes insipidus or primary polydipsia,
13
___________________
12
11
10
9
0
AVP levels were comparable at any given level of
plasma osmolality. AVP levels in patients with
pituitary diabetes insipidus were clearly below those
of normals; they were still measurable in the studies
of Robertson et a! ([20], Fig. 1) but were undetectable
in the studies of Husain et al ([19], Table 1). Of
interest is the question of whether or not AVP levels
go to zero with maximal hydration; in both studies
shown in Table 1, measurable amounts were still
present in normal subjects undergoing water diuresis.
A striking increase in AVP levels was found following
phlebotomy in sheep and rabbits [19], and following
cigarette smoking in humans [18, 19]. In a study in a
single normal subject, Arfonad-induced hypotension
increased AVP levels sharply [20]. In four subjects
with inappropriate ADH secretion, Beardwell [18]
found very high AVP levels ranging from 24 to 102
pg/mi. Thus, the radioimmunoassay technique has
yielded reasonable values for plasma AVP in a variety
of normal and pathologic states.
Binding of neurohypophysial hormones to receptors.
Vasopressin and other neurohypophysial hormones
bind reversibly to receptors on the basolateral surface
of their target cells. Binding to the receptor and
activation of adenylate cyclase can be seen with
hormone analogues lacking a disulfide bridge [22—24],
and it would now appear that the specificity of binding
of neurohypophysial hormones depends on the exact
three-dimensional "fit" of a particular hormone into
its receptor site. Walter and Urry [25] have constructed
three-dimensional models of oxytocin and lysine
vasopressin in which the molecule is arranged in a
rather complex series of turns and foldings (Fig. 2),
leaving certain residues free to react with the binding
site and others to initiate the hormonal response.
310 Two recent studies have addressed themselves to the
problem of vasopressin binding to "purified" mem-
brane fractions rich in adenylate cyclase. Both em-
ployed plasma membranes from pig renal medulla.
Bockaert and co-workers [26] carried out a detailed
• Primary polydipsia (N= 2)
A Nephrogenic diabetes insipidus (N=2)
® Pituitary diabetes insipidus (N= 8)
. A A
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Fig. 1. The relationship of plasma A VP to plasma ostuolality in
normal subjects and patients with polyuria of diverse etiologies.
Reprinted from 120].
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kinetic analysis of the binding of tritiated lysine vaso-
pressin to medullary plasma membranes. They found
that the saturation of the vasopressin receptors oc-
curred in a dose range identical to that producing
dose-dependent activation of adenyl cyclase (l0- to
10-10 M). There was a striking similarity between the
relative affinities of vasopressin, oxytocin and (0-Me)
Tyr2-oxytocin for the binding sites, and the ability of
these compounds to activate the enzyme. Vasopressin
binding was reversible; when the medium concentra-
tion of hormone was lowered by dilution from 10
to 5x 10 M, virtually all of the hormone initially
bound at 108 M left the receptor sites. The authors
noted a delay of approximately 10 mm in reaching
maximal receptor binding of a given concentration
(108 M) of vasopressin. Maximal activation of the
enzyme was similarly delayed, and the authors con-
cluded from the time course of binding and activation
that enzyme activation was a function of the number
of receptor sites occupied rather than the rate of turn-
over of the hormonal molecules on the receptor sites.
The effect of calcium on the binding of tritiated lysine
vasopressin to isolated membranes of pig renal medulla
was reported by Campbell, Woodward and Borberg[27]. At concentrations of 1 to 10 mi, calcium
inhibited vasopressin binding with complete inhibition
at 10 m. Lower concentrations of calcium (10-6 to
10 M) inhibited both basal and vasopressin-stimu-
lated activity of the core enzyme with complete
inhibition at 10 M calcium. Similar inhibition of
adenylate cyclase had been reported by Marumo and
Edelman [28]. These findings suggest two points in
the vasopressin-adenylate cyclase sequence at which
calcium may exert an inhibitory effect: 1) the receptor
site; 2) the core enzyme.
A number of problems related to membrane frac-
tionation techniques make interpretation of these
experiments difficult. For example, the concentration
of vasopressin needed to activate adenylate cyclase in
the broken cell preparation and the time required for
activation are both greater than in the intact animal,
where 10- ' to 10_12 M concentrations of AVP are
rapid and effective. It is possible that the sensitivity of
the receptor-adenylate cyclase system is reduced by the
method of preparation. Further, until more is known
about the location of the enzyme in the membrane
fragments (for example, whether the enzyme occupies
the inner or outer surface of membrane vesicles), it is
difficult to relate the millimolar concentrations of
calcium used in these experiments to the true levels of
calcium that the enzyme is exposed to in the intact cell.
Nevertheless, it is useful to note the following con-
clusions from these studies even though they require
further confirmation: 1) The binding of vasopressin
by membrane receptors appears to be reversible and
permits the simplest possible model for water diuresis
and antidiuresis. During antidiuresis, when plasma
vasopressin levels are high, receptor occupancy is
high; when vasopressin levels fall during water diuresis,
vasopressin leaves the renal receptor sites. 2) The
ability of calcium to inhibit vasopressin-induced water
reabsorption by the kidney [29] and the toad bladder
may involve a direct inhibitory action of calcium on
adenylate cyclase, and a second action in blocking the
attachment of vasopressin to membrane receptors.
3) Activation of adenylate cyclase may be a function
of the total receptor sites occupied by vasopressin,
rather than rate of turnover of hormone.
Activation and control of cyclic AMP
Activation of adenylate cyclase. Activation of adeny-
late cyclase by vasopressin accelerates the production
of adenosine 3',5' monophosphate (cyclic AMP) from
ATP. Cyclic AMP levels within the cell rise as shown
in some representative tissues in Table 2, part A. The
increase is modest (approximately threefold) in toad
bladder epithelial cells, and more pronounced in rat
inner and outer medulla. It is important to note that
the cyclic AMP levels within the cell represent a balance
between production by adenylate cyclase and destruc-
tion by the enzyme cyclic nucleotide phosphodiester-
ase. Thus, the concentration of cyclic AMP is far
below that which would be achieved if phosphodi-
esterase were inhibited. In part B of Table 2, data are
shown for toad bladder epithelial cells incubated in
the presence of such an inhibitor of phosphodiesterase:
10 mrt theophylline. A more pronounced response to
25 mU/mi vasopressin is apparent. Even higher levels
Fig. 2. Hypothetical model of the biologically active conformation
of oxytocin. Reprinted from WALTER R: Experientia 28:959—
960, 1972.
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Table 2. Intracellular cyclic AMP levels
Vasopressin
Absent Present
A Intact cells
Toad bladder epith. cells [52]a 8.9 26.3k'
Rat inner medulla [42] 3.5 36.81
Rat outer medulla [42] 3.8 1 10d
B Intact cells+ theophylline
Toad bladder epith. cells [52] 15.0 81.51
a Reference
I >< 10-12 M/mg protein; 25 mU/ml vasopressin
x 10 M/g wet tissue; 50 mU/ml vasopressin
x 10 M/g wet tissue; 1 mU/mI vasopressin
e x 10-12 M/mg protein; 25 mU/ml vasopressin
of cyclic AMP (approximately 200 x 10-12 M/mg) are
found in the theophylline-treated system if higher
concentrations of vasopressin are used [30]. From
these experiments it is clear that adenyl cyclase is
capable of generating far higher levels of cyclic AMP
than are seen in the normally functioning cell,2 and
that phosphodiesterase plays a major role in main-
taining a low level of cyclic AMP.
Agents other than phosphodiesterase influence
cyclic AMP levels: these include calcium, magnesium,
prostaglandins, adrenergic agents and adrenal steroids.
The actions of these agents will be briefly described;
the reader is referred to the review by Handler and
Orloff [3] for a more detailed treatment.
Calcium. As already noted, calcium inhibits the
hydro-osmotic effect of vasopressin on receptor cells
in the kidney and in the toad bladder. Bentley [32]
observed that raising the calcium concentration in the
solution bathing the serosal (blood) side of the toad
bladder significantly reduced osmotic water flow in
response to submaximal concentrations of vaso-
pressin; an elevated concentration of magnesium had
the same effect. An increased concentration of calcium
or magnesium did not inhibit the increase in short-
circuit current (active sodium transport), however [33],
and it was concluded that two of the effects of vaso-
pressin, on sodium and water movement, could be
separated. That conclusion was confirmed by Peterson
and Edelman [34], who went on to show that an
elevated calcium concentration had no effect on water
2 Eggena, Schwartz and Walter [31] have shown that certain
analogues of vasopressin can produce a full hydro-osmotic
response in the toad bladder, but have only about 30% of the
stimulatory effect of arginine vasopressin on adenyl cyclase.
Thus, the cyclic AMP produced by arginine vasopressin in excess
of that achieved by less potent analogues is not translated into
a hydro-osmotic response. This has been termed "receptor
reserve."
movement or short-circuit current stimulated by cyclic
AMP. This finding placed the site of calcium inhibition
of water movement at or before the generation of
cyclic AMP. The site could be at the vasopressin
receptor, or directly at adenyl cyclase; evidence exists
for an inhibitory action of calcium at both sites [27,
28, 35]. These findings have made it necessary to
consider at least two independent pathways for the
action of vasopressin, the first directed towards
osmotic water flow (and probably urea movement)
across the cell, the second directed towards the entry
of sodium across the luminal membrane. Both actions
are mediated by cyclic AMP, but the fact that high
concentrations of calcium can dissociate the water and
sodium response to vasopressin suggests that there
are separate adenyl cyclases, and the pools of cyclic
AMP they generate remain separate from each other.
There may also be two separate vasopressin receptors,
one of which is blocked by calcium.
Prostaglandins. The prostaglandins, a group of
naturally occurring long chain fatty acids, exhibit a
variety of inhibitory and stimulatory effects on the
actions of hormones on receptor cells [36]. In the
isolated collecting tubule, prostaglandin E1 (PGEI)
inhibits the antidiuretic action of vasopressin [37]; a
comparable inhibitory effect is seen in the toad bladder
[38—40]. Bergstrom [41] had originally proposed that
the prostaglandins acted as modulators of adenylate
cyclase, and the observation by Grantham and Orloff
[37] that PGE1 inhibited the effect of submaximal
concentrations of vasopressin on water flow across
the isolated rabbit collecting tubule, but not cyclic
AMP-induced water flow, supported Bergstrom's
proposal. On the basis of these observations, one
would expect PGE1 to decrease adenyl cyclase activity
and cyclic AMP levels in vasopressin-treated cells.
This has generally been the case: in homogenates of
hamster medulla, for example, 10 M PGE1 signi-
ficantly inhibited adenyl cyclase activity in response to
vasopressin [28]. Studies of slices of rat inner and outer
renal medulla by Beck et al [42] showed that PGE1
reduced the response of intracellular cyclic AMP to
submaximal concentrations of vasopressin. Studies in
the toad bladder failed in two cases [43, 44] to show
an inhibitory effect of PGE1 on adenyl cyclase, and, in
a third case [45] showed an inhibitory effect at only
one concentration of arginine oxytocin. Omachi et al
[30] have recently reported that in intact toad bladder
epithelial cells incubated both with and without 10 mM
theophylline, PGE1 produced a greater than 50%
inhibition of vasopressin-stimulated cyclic AMP
levels. Thus, in amphibian and mammalian receptor
cells, there is evidence that PGE1 exerts its modulating
effect on vasopressin at the adenyl cyclase step.
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The "adenylate cyclase step," however, is a broad
description that could include the vasopressin recep-
tors themselves, an intermediate step between receptor
and enzyme, or an allosteric or substrate binding site
in the core enzyme. In addition, there appear to be
differences in the effect of PGE1 on mammalian and
nonmammalian receptor cells in the absence of vaso-
pressin. In the isolated, perfused rabbit collecting
tubule, PGE1 (l0- M) produced a slight increase in
water flow in the absence of vasopressin, in contrast
to its inhibitory effect in the vasopressin-treated
tubule [37]. In slices of rat outer medulla, high
concentrations of PGE1 (10-6 M) produced a sharp
rise in cyclic AMP; this effect was not seen in the
inner medulla [42]. The fact that PGE1 can induce a
small osmotic flow in the absence of vasopressin, that
it increases cyclic AMP production and that it inhibits
the more potent effect of vasopressin on water flow,
supports the view that in the mammalian tubule vaso-
pressin and PGE1 may compete for a site at or close
to adenylate cyclase [37, 42].
In the toad bladder, PGE1 has not been shown to
increase water flow in the absence of vasopressin [43,
47]. PGE1 at 2.5 x 106 M does increase cyclic AMP
levels in the resting cell [30, 45]; this apparently
contradictory finding may mean that a cyclic AMP
pooi unrelated to osmotic water flow but related to
some other function, such as active sodium transport,
is increased by PGE1 [46]. (This may also be partly
true in the mammalian renal tubule.) The possibility
that this cyclic AMP pool in the toad bladder is un-
related to water flow is strengthened by observations
in two laboratories that PGE1 inhibits water flow
induced by theophylline [38, 39]. Since theophylline
promotes water flow by inhibiting phosphodiesterase,
and PGE1 has no effect on the access of theophylline
to phosphodiesterase [45], it appears likely that in the
toad bladder, PGE1 inhibits, rather than stimulates,
the adenylate cyclase involved in water flow. Thus, in
the toad bladder, the evidence favors a direct, non-
competitive inhibitory action of PGE1 on adenylate
cyclase [31].
Irrespective of its exact mechanism of action, PGE1
appears to be a modulator of the action of vasopressin.
The endogenous production of small amounts of
PGE1 may prevent inappropriate responses of the
tubule to small amounts of residual vasopressin [38].
An attempt to demonstrate a regulatory role for
endogenous prostaglandins in the toad bladder has not
yielded clear-cut results [48], and solution of this impor-
tant problem may require better techniques for measur-
ing trace amounts of prostaglandins in receptor tissues.
Adrenal steroids. Aldosterone and other adrenal
steroids enhance the permeability response of the toad
bladder to vasopressin and exogenous cyclic AMP
[49—50], under certain experimental conditions. This
"permissive effect" of adrenal steroids is seen in the
response of both active sodium transport [50—Si] and
osmotic water flow [50] to vasopressin. Recent studies
by Stoff et a! [52, 53] have shown that this accelerated
response is associated in the case of aldosterone with
an increase in intracellular cyclic AMP, and that the
elevated cyclic AMP levels, in turn, are the result of
steroid-elicited decrease in cyclic AMP degradation by
phosphodiesterase. These workers have suggested that
aldosterone may initiate the synthesis of a protein
inhibitor of phosphodiesterase. A comparable sup-
pression of phosphodiesterase by dexamethasone has
been observed in cultured hepatoma cells [54].
The applicability of these findings to human renal
physiology is complicated by other effects adrenal
hormones have on the tubule, for example, in stimu-
lating sodium transport by the ascending levels of the
ioop of Henle. However, as suggested by Handler et a!
[50], the abnormally low free water reabsorption by
the kidneys of adrenalectomized animals, and its
correction by adrenal steroids [55], may be due in
part to the permissive effect of steroids on the perme-
ability response of the tubule to vasopressin.
Adrenergic agents. Adrenergic agents modify water
excretion in the mammalian kidney, with beta-adrener-
gic stimuli producing an antidiuretic effect [56, 57] and
aipha-adrenergic agents a diuretic effect [58—60]. Beck
and co-workers [61] showed that epinephrine increases
both cortical and medullary cyclic AMP in the dog
kidney, and that this effect is due to the beta- rather
than the alpha-adrenergic action of this drug. Iso-
proteranol also increased medullary cyclic AMP. In
the presence of vasopressin, aipha-adrenergic stimuli
decreased the usual stimulus of vasopressin on cyclic
AMP. These effects of alpha- and beta-adrenergic
agents on medullary cyclic AMP levels were consistent
with their effects on the intact kidney. Handler,
Bensinger and Orloff [62] have proposed that alpha-
adrenergic agents decrease cyclic AMP production by
inhibiting adenylate cyclase. Beta agents may stimulate
adenylate cyclase, but this was less clearly shown in
their studies with the toad bladder.
Beyond Cyclic AMP. What steps lie beyond cyclic
AMP, ending with the alteration of the luminal cell
membrane? It has been thought that the major step
is the activation of a protein kinase by cyclic AMP,
with a resultant net transfer of a phosphate from ATP
of a protein [63, 64]. This protein might conceivably
be part of the membrane itself and play an important
role in the permeability change in the membrane.
Recent studies by Greengard and his colleagues [65,
66] have indicated that cyclic AMP has an effect
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opposite to that predicted from earlier studies. Phos-
phorylation of a protein (protein D) in intact toad
bladder epithelial cells, homogenates and membrane-
rich subfractions was decreased rather than increased
by vasopressin and cyclic AMP. This appeared to be
due to the activation of a membrane-bound phospha-
tase by cyclic AMP, with the consequent net dephos-
phorylation of protein D. (The contribution of a
kinase in this system could not be ruled out, but
appeared to be less significant than that of the phos-
phatase.) The existence of such a phosphatase had been
described by Dousa, Sands and Hechter [67] in studies
of bovine kidney. This observation requires confirma-
tion.
Summary. Fig. 3 summarizes in diagrammatic form
what is currently believed to be the sequence of steps
from the attachment of vasopressin to the alteration
in the luminal cell membrane. The points at which
calcium, prostaglandin E1, adrenal steroids and alpha-
adrenergic agents are thought to act are indicated.
Alteration of the cell membrane
The final step in the sequence initiated by vaso-
pressin is a marked change in the permeability of the
luminal cell membrane. Evidence that this portion of
the cell membrane is indeed the barrier transformed
by vasopressin has come from studies of frog skin [68],
toad bladder [69, 70], rabbit cortical collecting tubule
[71, 72] and rat collecting duct [1]. In general, these
studies have shown that entry of water or urea across
the luminal permeability barrier, as demonstrated by
cell swelling or labeling of cell water by isotopic urea,
is accelerated by vasopressin, an effect which can be
most readily explained by an increase in the perme-
ability of this barrier. It appears unlikely that vaso-
LUMINAL
MEMBRANE
Fig. 3. Schematic sequence of the steps in the action of vasopressin.
Two receptors (R1 and R2) are shown; R2 and its associated
adenylate cyclase are hypothetical. as is the second cyclic AMP
pool indicated with dashed lines. A phosphatase, removing
phosphate from a protein at or near the luminal membrane, is
shown, along with a kinase, which could phosphorylate the
membrane. The proposed inhibitory sites of calcium, PGE1,
alpha-adrenergic agents and aldosterone are shown.
pressin has any effect on the tight junction linking
adjacent cells [72].
The extent to which vasopressin increases the per-
meability of the luminal membrane is impressive, both
in the mammalian collecting tubule and in anuran
tissue such as toad bladder and toad skin. Osmotic
water flow increases seven times, and urea movement
one and one-half times across the rat collecting duct
[73] following vasopressin; the increases in water flow
and urea movement across the toad bladder are
50-fold and sixfold, respectively [69, 70]. The active
transport of sodium is also increased by vasopressin,
as well as the movement of a large number of solutes;
indeed, it now appears that the effect of vasopressin
on permeability is a very broad one involving not only
hydrophilic but lipophilic solutes ([74], Levine, Em-
horn, Franki and Hays, unpublished observations).
In the following section, the nature of the effect of
vasopressin on the cell membrane will be considered.
The pore enlargement hypothesis. In 1953, Koefoed-
Johnsen and Ussing [75] published their important
analysis of water flow across the frog skin. They had
noted that while there was a greater than twofold
increase in osmotic water flow across the skin following
vasopressin, the diffusion rate of isotopically labeled
water (the rate at which individual water molecules
penetrated the skin) increased by only 10%. This
apparent discrepancy between osmotic flow and net
flow determined by diffusion could be explained if
vasopressin enlarged pores (aqueous channels) in the
membrane. Since the rate of osmotic flow through a
porous structure would be determined by Poiseuille's
law, it would be a function of the fourth power of the
pore radius. The rate of diffusion of labeled water, on
the other hand, would be a function of pore area, or r2.
Thus, with any increase in pore radius, osmotic flow
would increase to a far greater extent than diffusion.
This proposal accounted not only for the discrepancy
between osmotic and diffusional net flow in the frog
skin, but for the even greater apparent discrepancies
in other epithelial tissues such as frog gastric mucosa,
where the ratio of the osmotic to diffusional coefficients
was 25 to 1 [76], and the vasopressin-treated toad
bladder, where the ratio was greater than 100 to 1 [69].
Since rather large pore radii of the order of 15 to 40 A
would be required to account for these ratios, one
would predict that even large solutes of the size of
sucrose would penetrate tissues like the toad bladder
more rapidly following vasopressin. Since this was not
the case [77], it was necessary to propose that the
luminal membrane might include two barriers in
series, one a fine diffusion barrier capable of sieving
out •solutes, and the second a vasopressin-sensitive
barrier, which becomes highly porous in the presence
PGE
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of hormone and is responsible for the Poiseuille flow
of water [78, 79]. This appeared to answer the question
of how selectivity towards solutes could exist in the
presence of large pores.
The pore enlargement hypothesis was supported by
another observation: in the presence of net water
flow there was an apparent acceleration of solute
movement in the direction of the water flow [77, 78].
This "solvent drag" effect would only be seen if
water and solutes interacted in aqueous channels, and
thus it provided strong evidence for the presence of
such channels in cell membranes.
Unstirred layers. An important part of the pore
enlargement hypothesis was the small contribution
that the process of diffusion appeared to make to total
water flow. However, it has been recognized for some
time that stagnant (unstirred) layers of water sur-
rounding membranes can impede the rate of diffusion
of molecules moving across the membrane [80—83].
Indeed, if the molecule is one that penetrates the mem-
brane phase at a rapid rate (for example, a water
molecule) the unstirred layers can provide a resistance
to diffusion many times that of the cell membrane
itself. If to the unstirred layers in series with the luminal
cell membrane one adds the cell cytoplasm, the inter-
cellular spaces and the layer of connective tissue that
supports many epithelial structures, it becomes clear
that the rate of movement of isotopic water across the
luminal membrane may be exceedingly fast, and yet
would be masked by the rate-limiting effect of the
unstirred layers. This fact is shown diagramatically in
Fig. 4.
In studies of the unstirred layer effect in the toad
Fig. 4. Extraneous barriers in an epithelial tissue. The luminal
membrane (under magnifying glass) is the membrane trans-
formed by vasopressin. In series with the membrane are unstirred
layers in the bulk solution, cell cytoplasm and organelles, baso-
lateral cell membrane, intercellular channels and the supporting
layer (stippled layer). Reprinted from [85].
bladder [84, 85] it has been shown that the unstirred
layers on either side of the membrane, plus the thick
supporting layer, provide a major fraction of the
resistance to the diffusion of isotopic water, but
virtually no resistance to osmotic flow. The equations
used in this estimate are included in references [84—86].
When one factors out the contribution of these ex-
traneous layers, one finds that the diffusion rate of
water across the epithelial cell layer increases sharply
following vasopressin approximately 20-fold, rather
than the 1.7-fold increase thought to take place in
earlier experiments, in which the unstirred layer effect
was not considered [69]. Thus, the discrepancy
between osmotic flow and diffusion is reduced con-
siderably by these studies; a further reduction would
be anticipated when additional unstirred layers in the
cytoplasm are taken into account (see below).
The conclusion that the rate of diffusion of water
across the cell membrane is really very rapid was
supported by the studies of Parisi and Piccinni [87],
who measured the diffusion rate of tritiated water
across the luminal border of the toad bladder epi-
thelial cell over very short time periods. They con-
cluded that uptake was rapid enough to account
entirely for total water flow following vasopressin, and
that barriers other than the luminal barrier had led to
underestimation of the true rate of diffusion across the
luminal membrane.
As pointed out by Handler and Orloff [3], the
problem of unstirred layers in the renal tubule differs
from that in flat epithelial structures such as the toad
bladder. The luminal radius of a structure such as the
cortical collecting tubule of the rabbit is less than 10 ,
providing little distance for an unstirred layer effect.
There is only a thin supporting layer, and the external
unstirred layer is thought to be small. Yet there is a
large discrepancy between osmotic flow and diffusional
net flow following vasopressin. The solution to this
problem may lie in the retarding effect of the cell
cytoplasm and other cellular structures. Schafer and
Andreoli [88] have estimated in the vasopressin-
treated isolated rabbit cortical collecting tubule that
the diffusional resistance of structures beyond the
luminal membrane is 15 to 25 times that of an equiva-
lent thickness (6 z) of water. Correcting for this
"unstirred layer" effect increases the estimated dif-
fusion rate of water across the luminal membrane
enough to account for all of the water flow across this
segment of the collecting tubule.
Thus, in several types of vasopressin-sensitive
epithelia, there is evidence that the diffusion of
individual water molecules across the luminal mem-
brane is an exceedingly fast process and may account
for the osmotic water flow observed. The studies cited
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do not permit us to distinguish between a "pure"
diffusion model, in which water dissolves in the mem-
brane more readily following vasopressin, and a model
in which vasopressin simply increases the number of
small aqueous channels, close to the size of a water
molecule. The water in such channels may have an
"ice-like" structure, judging from the high activation
energy for water diffusion [89].
Independent pathways for water and solutes. The
apparent interaction between water and solutes such as
urea, as seen in the solvent drag effect, supported the
idea that aqueous channels large enough to admit
water and solutes were present in the cell membrane.
A number of studies, however, raise the question of
how extensive the solvent drag effect is, and where the
major site of solute—solvent interaction is located in
vasopressin-sensitive tissues. In the isolated rabbit
cortical collecting tubule, there appears to be a com-
plete dissociation between water and urea movement;
water movement increases strikingly following vaso-
pressin, but urea movement is unchanged [90]. In the
toad bladder, urea movement was accelerated in the
direction of net water flow when the experiments were
carried out in conventional diffusion chambers, where
bubbling provided the means of stirring the solutions
[77]. However, in mechanically stirred chambers, the
solvent drag effect on acetamide, an amide closely
related to urea, was not apparent [85]. This finding
suggests that the apparent solvent drag effect in
relatively simple epithelia such as the toad bladder
may be the result of the accumulation of isotopically
labeled solute in unstirred layers near the luminal
membrane, as water flow proceeds from lumen to
serosa. Dilution of solute, on the other hand, would
occur near the serosal membrane. This asymmetry of
solute concentration would produce an asymmetry of
flux rates in the two directions; mechanical stirring
would tend to reduce solute asymmetry and hence
reduce the apparent solvent drag effect. In more
complex epithelia such as toad skin the opportunity
for solute accumulation, and for water-solute inter-
action in intercellular channels is greatly increased.
Ussing [91] has recently reported that sucrose, a large
molecule whose diffusion pathway across the toad skin
may be between cells, showed a pronounced solvent
drag effect, while glycerol, a small molecule which
probably penetrates the cell membrane, showed little
or no solvent drag effect following vasopressin. He
concluded that the long intercellular pathway afforded
a maximum opportunity for solvent drag, while any
solvent drag occurring across the cell membrane
would be small because of the short path length
involved. It seems reasonable to conclude that solute—
solvent coupling may be most important in the inter-
cv cv cv cv
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cellular channels, and that its existence in the cell
membrane is open to question.
A more clear-cut demonstration of the independence
of solute and water movement across the toad bladder
was prompted by the observation of Macey and Far-
mer [92] that phloretin, the aglucone of phlorizin,
blocked urea movement into the red cell, but had no
effect on the entry of water. This proved to be the case
in the toad bladder [93]; in the presence of l0 M
phloretin in the luminal bathing medium, urea move-
ment was markedly inhibited both before and after
vasopressin, but water flow was unimpaired (Fig. 5).
Identical results were obtained when 10-s M chromate
was placed in the luminal bathing medium [94].
Phloretin inhibited the movement of all amides tested,
and certain nonamides (thiourea, formaldehyde) as
well. Other solutes, such as ethanol and ethylene glycol,
whose movement is accelerated by vasopressin, were
not blocked by phloretin. Phioretin also blocks urea
reabsorption by the dogfish kidney [95].
These findings indicate that many solutes, notably
the amides, move across the luminal membrane of the
bladder by a pathway which can be experimentally
separated from the osmotic flow of water. Recent
studies [96] have shown that this pathway has one of
the properties of facilitated diffusion: it exhibits
saturation at high substrate levels. In the presence of
125 and 150 mri acetamide on both sides of the bladder,
for example, the movement of acetamide departs
significantly from linearity (Fig. 6), indicating that at
some point in the membrane there are a limited num-
ber of binding sites or recognition sites for acetamide
which become saturated at high substrate concentra-
tions. Other amides, such as methylurea, exhibit this
type of self-saturation even more strikingly (LEVINE
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Fig. 5. The effect of 1O M phloretin on the osmotic flow of water
(open bars) and the movement of urea (hatched bars), in untreated
bladders (left-hand panel) and phloretin-treated bladders (right-
hand panel). C, control period (vasopressin absent); V, following
vasopressin. Reprinted from [93].
and HAYS, unpublished observations). There is also
competition between different amides for binding sites:
thus, propionamide and methylurea both inhibit the
movement of urea across the bladder. Eggena [97] has
recently shown that thiourea inhibits urea movement
across the bladder.
Summary. Water and solute movement across the
cell membrane in response to vasopressin appears to
have the following characteristics: 1) Water movement
across the luminal membrane may take place largely,
if not completely, by the process of diffusion. This
does not rule out the existence of small continuous
aqueous channels, but such channels might be close
to the size of a water molecule. 2) Water movement
can be experimentally dissociated from that of many
solutes, notably the amides. 3) Solvent drag may well
take place in intercellular channels, but there is no
compelling evidence that it takes place in membrane
pores. 4) The movement of amides and possibly other
solutes appears to be by facilitated diffusion, and to
exhibit saturation. Agents such as phioretin and
chromate block this "amide pathway." Not all solutes
move via this pathway; their mode of passage is as yet
unknown. The proposed pathways are shown dia-
gramatically in Fig. 7.
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Fig. 7. Schematic view of proposed pathways for water and solute
movement across the toad bladder following vasopressin. Amides
move via a facilitated transport system in which saturation,
mutual inhibition by amides and inhibition by phloretin take
place. Other vasopressin-sensitive molecules, such as water,
ethylene glycol and ethanol, move by one or more independent
pathways, unaffected by phloretin. Vasopressin-insensitive
solutes may move via additional pathways. Reprinted from [94].
Alterations observed in the luminal membrane. Up
to this point, the case for a vasopressin-induced
change in the diffusional properties of the luminal
membrane has rested largely on permeability studies.
Several articles have appeared recently reporting direct
observations on the change in the membrane following
vasopressin. Grantham [98] has shown that the
physical deformability of the urinary surface of rabbit
collecting duct cells is increased following vasopressin.
The measurement was made by determining the nega-
tive pressure required to suck a hemispherical bulge of
the cells' urinary surface into the tip of a micropipette.
There was a reduction of approximately 25% in the
pressure recorded in the vasopressin-treated tubules.
Masur, Holtzman and Walter [99] have reported that
the plasma membranes of secretory granules lying
below the luminal surface of the toad bladder become
continuous with the surface membrane following
vasopressin, permitting the granules to discharge their
contents, which then may coat the cell surface. This
type of exocytosis was apparent two hours after the
addition of vasopressin, which raises a question of its
relationship to the rapid physiologic action of the
hormone; however, it may be necessary to wait until
enough granules have attached to the surface to
demonstrate this effect. Taylor et al [100] have called
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Fig. 6. Velocity of acetamide movement across the toad bladder
in the presence of increasing concentrations of acetamide in both
bathing media. Reprinted from [96].
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attention to the possible role of microtubules and
microfilaments in the action of vasopressin. Several
agents which disrupt microtubules or microfilaments,
including coichicine, vinbiastine and cytochalasin B,
inhibit the effect of vasopressin and cyclic AMP on
osmotic water flow across the toad bladder. It is
possible that microtubules and microfilaments, which
were observed by the authors in the microvilli and
subplasmalemmal region of the apical surface, exert
their effects by releasing secretion granules, by their
involvement in cytoplasmic streaming, or in some other
fashion. A second possibility is that the agents em-
ployed in these studies have a direct action on the cell
membrane, rather than on microtubules and micro-
filaments. Wunderlich, Muller and Speth [101], for
example, have proposed a direct action of coichicine
on the alveolar membrane of the protozoan Tetra-
hymena pyrjformis, in studies using freeze-fracture
techniques.
Oral agents in diabetes insipidus3
Although exogenous vasopressin is the most fre-
quently utilized treatment for diabetes insipidus, the
occurrence of occasional allergic, irritative or vaso-
constrictive reactions, and the inconvenience of paren-
teral administration, makes alternative modes of treat-
ment desirable. Over the past several years, the anti-
diuretic effects of a number of orally administered
agents have become apparent.
Thiazides and other diuretics. Crawford and Ken-
nedy [1021 first showed that thiazides significantly
reduced urine volume in diabetes insipidus, with an
increase in. urine volume toward, although not above,
isosmotic levels. The antidiuretic effect appears to be
the result of mild sodium depletion, with an increase
in proximal salt and water reabsorption, and a con-
sequent decrease in the delivery of fluid to the diluting
segment of the nephron [103]. Other diuretics, as well
as strict salt restriction, can effect or at least preserve
a comparable antidiuresis [102, 104, 105]. Because its
action does not directly involve vasopressin or the
vasopressin-sensitive regions of the nephron, thiazides
are the drugs of choice in nephrogenic diabetes
insipidus. Their inability to produce a hypertonic
urine, as well as their hyperglycemic, hyperuricemic
and occasional hematologic side effects make them
less than ideal for long-term administration in other
forms of diabetes insipidus.
While this section deals with the action of the orally ad-
ministered agents, it should be noted that the drug of choice
is probably the ong-acting vasopressin analogue dDAVP
[150, 1511.
Chiorpropamide and other sulfonylureas. The anti-
diuretic effect of chlorpropamide was first observed by
Arduino, Ferraz and Rodrigues [106] in a patient with
idiopathic diabetes insipidus who took the drug mis-
takenly and noted a striking diminution in urine
volume. The antidiuretic effect of chiorpropamide has
been confirmed by many investigators in both adults
and children with vasopressin-responsive diabetes
insipidus [107—115]. It is ineffective in the nephrogenic
form of the disease and has produced symptomatic
hypoglycemia in a significant percentage of patients
[116].
Chiorpropamide potentiates the antidiuretic effect
of vasopressin. This was demonstrated in the toad
bladder, where chiorpropamide alone had no effect
on osmotic water flow but increased the sensitivity of
the bladder to submaximal concentrations of vaso-
pressin [117, 118]. This "sensitizing" effect of chior-
propamide was confirmed in studies of rats with
hereditary hypothalamic diabetes insipidus [119] and
dogs undergoing water diuresis [120]. In both cases,
chiorpropamide alone had no antidiuretic effect, but
it enhanced the effect of exogenous vasopressin. It was
suggested [118] that chiorpropamide exerted its anti-
diuretic effect in man by sensitizing the renal tubule to
the trace amounts of vasopressin that remained in cir-
culation. The observation by Miller and Moses [121]
that there was a significant correlation between the
ability of patients to respond to chlorpropamide and
their ability to respond to water deprivation by reducing
free water clearance appeared to support this view.
However, the concept of "peripheral sensitization"
did not appear adequate to explain several observa-
tions: 1) chiorpropamide impairs water excretion in
water-loaded normal subjects [122] and 2) dilutional
hyponatremia has been reported in patients with
diabetes mellitus treated with chiorpropamide [123—
126]. If chlorpropamide acted only by increasing
peripheral sensitivity, this would imply that water
loading does not completely inhibit the release of
ADH. This may indeed be the case (see Table 1);
however, Miller and Moses [127, 128] have proposed
that in addition to its peripheral action, chlorpro-
pamide stimulates the central release of vasopressin.
They have found an increase in the urinary excretion
of ADH, as determined by radioimmunoassay, in
water-loaded patients given chlorpropamide. While
these findings require confirmation, ideally with
measurements of plasma vasopressin levels, they are
of great interest.
With respect to other sulfonylureas, tolbutamide has
slight antidiuretic activity, especially if given intra-
venously [129]; hyponatremia due to tolbutamide has
been reported only infrequently [130]. Tolazamide,
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acetohexamide and glyburide, three other antihyper-
glycemic sulfonylurea compounds, enhance water
excretion in water-loaded normal subjects, in contrast
to the action of chlorpropamide [1311, and glyburide
has been reported to cause an increase in polyuria in
patients with central diabetes insipidus [132]. Gly-
buride causes no change in urinary ADH excretion
in hydrated normal subjects, and does not alter the
excretion of radioactive ADH in the Brattleboro rat
with total ADH deficiency [131]. In addition, gly-
buride does not alter the action of infused ADH in
either man or the Brattleboro rat. Presumably, the
diuretic action of glyburide may be related to an
increase in glomerular filtration rate or a decrease in
proximal salt and water reabsorption, increasing
delivery to the diluting segments of the nephron.
Because of the hazard of water intoxication in
patients with cardiovascular disease treated with
chiorpropamide for diabetes mellitus, the substitu-
tion of other sulfonylureas which are not antidiuretic
has been recommended [131].
Cellular mechanism of action of chiorpropamide. As
already noted, chlorpropamide in low concentrations
(ito 3 x 10 M) has no direct effect on osmotic water
flow across the toad bladder, but enhances the effect
of submaximal concentrations of vasopressin [117,
118]. Chlorpropamide does not enhance the effect of
saturating levels of vasopressin [117, 118]. Chlorpro-
pamide also intensifies the inhibitory action of PGE1
on vasopressin-induced water flow in the toad bladder
[l33]. These observations, taken alone, suggest
that chlorpropamide acts at the adenyl cyclase step,
increasing the reactivity of the enzyme to both vaso-
pressin and PGE1. However, this single mode of action
would not account for a number of effects of this
agent: 1) At high concentrations (1 to 7 x l0- M)
chlorpropamide increases water permeability both in
the absence of vasopressin [133, 134] and in the pres-
ence of saturating levels of vasopressin [135], a result
consistent with a depressive effect of chlorpropamide
on phosphodiesterase. 2) The stimulatory effect of
cyclic AMP on water flow when added to the serosal
bathing medium is enhanced by mucosal chlorpro-
pamide [135] and diminished by serosal chlorpro-
pamide [117]. Urakabe et al have suggested that a
local chlorpropamide-induced decrease in membrane
permeability to cyclic AMP might be an additional
mechanism of increasing the levels of intracellularly
produced cyclic AMP, with a resultant increase in
water permeability [134]. 3) Recent measurements of
cellular cyclic AMP levels by Omachi et al [30] have
brought all of the foregoing explanations into question.
Inhibition of PGE1 has also been reported [152].
Those authors have found that chiorpropamide added
to bladders treated with vasopressin or theophylline
does not increase cyclic AMP levels above those
measured in the absence of chlorpropamide. On the
contrary, in the vasopressin-treated bladders, chlor-
propamide treatment caused a small reduction in
cyclic AMP levels. It becomes difficult, therefore, to
attribute the chlorpropamide-induced increase in
water permeability in vasopressin-treated bladders to
alterations in cyclic AMP levels, or to assign any
single step in the vasopressin-cyclic AMP-membrane
sequence as the point of action of chlorpropamide.
Analgesics. Although both aminopyrene [136] and
acetaminophen [137] have an antidiuretic action in
diabetes insipidus, the clinical usefulness of amino-
pyrine has been limited by its hematologic toxicity.
These analgesics appear to have a dual effect when
studied in the toad bladder: 1) They increase the
water permeability of the bladder in the absence of
vasopressin, as well as in the presence of both low and
saturating levels of vasopressin [133, 138, 139]. In
addition, they increase the response of the bladder to
exogenous cyclic AMP, suggesting an inhibitory action
on phosphodiesterase. Supporting evidence for this
hypothesis has been obtained by Lozada et al, although
they were able to find inhibition only at high analgesic
concentrations [133]. 2) Like chiorpropamide, the
phenylacetamide analgesics intensify the inhibitory
action of PGE1 on vasopressin-induced water flow
[133], a finding which might be most easily explained
by an action at adenyl cyclase as well.
Clofibrate. Recently, the hypolipidemic agent
clofibrate has been found to have an antidiuretic
action in patients with diabetes insipidus [140—142].
Clofibrate's mode of action has been clarified by
studies of Moses et al [143], who demonstrated a
decrease in urinary volume and free water clearance,
as well as an increase in urinary ADH excretion, in
patients with diabetes insipidus given clofibrate. These
findings correlated with the ability of these patients to
concentrate their urine and excrete ADH after de-
hydration. They suggested that clofibrate acts by
enhancing the subnormal excretion of ADH in patients
with diabetes insipidus, and that residual releasable
ADH is necessary for clofibrate to induce an anti-
diuresis. Clofibrate had no antidiuretic effect in rats
with hereditary hypothalamic diabetes insipidus,
and did not increase the antidiuretic response of these
rats to ADH; in fact, a small diuretic response was
seen.
Clofibrate interfered with the ability of both patients
and normal subjects to excrete a water load, and
prevented the water load from inhibiting ADH excre-
tion maximally in the normal subjects [143]. The
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antidiuretic effect of clofibrate thus appears to be
limited to increasing ADH release, without augment-
ing vasopressin's renal action, in contrast to chior-
propamide, which may affect release and renal action.
This is consistent with the observation that although
clofibrate and chlorpropamide are antidiuretic to
similar degrees in normal water-loaded subjects,
urinary ADH excretion is twice as great with clofibrate.
The lack of apparent renal effect of clofibrate is also
consistent with the findings of Shuchter and Hays (un-
published observations), who found no effect of
clofibrate on water permeability of the toad urinary
bladder either in the presence or the absence of vaso-
pressin.
Antineoplastic drugs. In the past several years, hypo-
natremia and water intoxication have been reported
as untoward side effects of the drugs cyclophos-
phamide and vincristine. Studies by DeFronzo et al
[144] have demonstrated a consistent impairment of
water excretion in 13 of 17 patients 4 to 12 hr after
intravenous administration of cyclophosphamide in
doses of 50 mg/kg or higher, as demonstrated by
decreased urine flow, weight gain, hyponatremia and
inappropriately concentrated urine. The changes in
urinary osmolality showed a close temporal relation-
ship to the appearance of alkylating metabolites of
cyclophosphamide in the urine and serum. No signi-
ficant changes in GFR or urinary sodium excretion
were observed. Although the mechanism of this anti-
diuresis has not been established, the water-loading
that these patients frequently undergo to prevent
cystitis and uric acid lithiasis makes testing for
hyponatremia especially important.
Vincristine neurotoxicity has been implicated in
several reports of apparent inappropriate ADH secre-
tion. Most of these occurred in children [145—147] and
at least one adult has been reported as well [148]. The
patients have responded well to fluid restriction.
Robertson, Bhoopalam and Zelkowitz [149] have
confirmed by radioimmunoassay the presence of ele-
vated ADH concentrations in this condition.
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